Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4932163 | 1.00 | MEN1 (0.45) | MEN1KMT2AL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL4934136 | 0.90 | MEN1 (0.47) | MEN1KMT2AL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL4934130 | 0.90 | MEN1 (0.47) | MEN1KMT2AL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL4939039 | 0.88 | GAA (0.43) | MEN1KMT2AL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL4939046 | 0.88 | GAA (0.43) | MEN1KMT2AL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL4935951 | 0.85 | LMNA (0.44) | MEN1KMT2AL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL4935961 | 0.85 | LMNA (0.44) | MEN1KMT2AL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL4933079 | 0.81 | HDAC6 (0.50) | L3MBTL1NPC1GAAHTTRECQL | |
| SCHEMBL4933087 | 0.81 | HDAC6 (0.50) | L3MBTL1NPC1GAAHTTRECQL | |
| SCHEMBL4937099 | 0.80 | MEN1 (0.48) | MEN1KMT2AL3MBTL1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1707560-A1 | HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE | Kureha Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | MEN1 3049/4885KMT2A 249/4885L3MBTL1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.